These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 15765299)

  • 1. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 5. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
    Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
    Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
    Sevinc A; Camci C
    Chemotherapy; 2009; 55(1):11-4. PubMed ID: 18974643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
    Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
    Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E; Judson I
    Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].
    Poveda A; Artigas V; Casado A; Cervera J; García Del Muro X; Antonio López-Guerrero J; López-Pousa A; Maurel J; Ortega L; Ramos R; Romero I; Safont MJ; Martín J;
    Cir Esp; 2008 Oct; 84 Suppl 1():1-21. PubMed ID: 19087862
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
    Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
    Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
    Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics.
    de Mestier P; des Guetz G
    World J Surg; 2005 Mar; 29(3):357-61; discussion 362. PubMed ID: 15706444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.